Isorhapontigenin (ISO) inhibits invasive bladder cancer formation In Vivo and human bladder cancer invasion In Vitro by targeting STAT1/FOXO1 axis

Cancer Prevention Research

Volumn 9, Issue 7, 2016, Pages 567-580

  Jiang, Guosong ^a   Wu, Amy D ^a   Huang, Chao ^a   Gu, Jiayan ^b   Zhang, Liping ^b   Huang, Haishan ^b   Liao, Xin ^a   Li, Jingxia ^a   Zhang, Dongyun ^a   Zeng, Xingruo ^a   Jin, Honglei ^a   Huang, Haojie ^c   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; ISORHAPONTIGENIN; MESSENGER RNA; STAT1 PROTEIN; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; GAMMA INTERFERON ACTIVATION FACTOR; INTERFERON STIMULATED GENE FACTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; GNETUM; GNETUM CLEISTOSTACHYUM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TRANSCRIPTION INITIATION; TUMOR INVASION; UPREGULATION; ANIMAL; BLADDER TUMOR; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; METABOLISM; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; FORKHEAD BOX PROTEIN O1; HUMANS; INTERFERON-STIMULATED GENE FACTOR 3; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; STILBENES; URINARY BLADDER NEOPLASMS;

EID: 84977103738     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0338     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-49.
3. Huang KS, Wang YH, Li RL, Lin M. Stilbene dimers from the lianas of Gnetum hainanense. Phytochemistry 2000; 54: 875-81.
4. Fang Y, Cao Z, Hou Q, Ma C, Yao C, Li J, et al. Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells. Mol Cancer Ther 2013; 12: 1492-503.
5. Fang Y, Yu Y, Hou Q, Zheng X, Zhang M, Zhang D, et al. The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by downregulating overexpression of antiapoptotic protein XIAP. J Biol Chem 2012; 287: 35234-43.
6. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120: 2479-87.
7. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene 2008; 27: 2312-9.
8. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr., DiStefano PS, et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002; 296: 530-4.
9. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68.
10. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 2002; 168: 5024-31.
11. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162: 613-22.
12. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011; 71: 3257-67.
13. Chen J, Huang Q, Wang F. Inhibition of FoxO1 nuclear exclusion prevents metastasis of Glioblastoma. Tumour Biol 2014; 35: 7195-200.
14. Kim TH, Jo SW, Lee YS, Kim YJ, Lee SC, KimWJ, et al. Forkhead box O-class 1 and forkhead box G1 as prognostic markers for bladder cancer. J Korean Med Sci 2009; 24: 468-73.
15. Lu H, Liu P, Pan Y, Huang H. Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1. Neoplasia 2011; 13: 854-63.
16. Essaghir A, DifN,Marbehant CY, Coffer PJ,Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 2009; 284: 10334-42.
17. Cao J, Rehemtulla A, Pavlaki M, Kozarekar P, Chiarelli C. Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 2005; 280: 10974-80.
18. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999; 274: 29130-7.
19. Zhang R, Wang Y, Li J, Jin H, Song S, Huang C. The Chinese herb isolate yuanhuacine (YHL-14) induces G2/M arrest in human cancer cells by upregulating p21 protein expression through an p53 protein-independent cascade. J Biol Chem 2014; 289: 6394-403.
20. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000; 27: 252-63.
21. Titus B, Frierson HF Jr, Conaway M, Ching K, Guise T, Chirgwin J, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005; 65: 7320-7.
22. Jin H, Yu Y, Hu Y, Lu C, Li J, Gu J, et al. Divergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell lines. Oncotarget 2015; 6: 522-36.
23. Song L, Li J, Zhang D, Liu ZG, Ye J, Zhan Q, et al. IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J Cell Biol 2006; 175: 607-17.
24. Song L, Li J, Ye J, Yu G, Ding J, Zhang D, et al. p85alpha acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. Mol Cell Biol 2007; 27: 2713-31.
25. Zhang D, Wang Y, Liang Y, Zhang M, Wei J, Zheng X, et al. Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration. J Cell Sci 2014; 127: 2920-33.
26. Liu J, Zhang D, Luo W, Yu Y, Yu J, Li J, et al. X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. J Biol Chem 2011; 286: 15630-40.
27. Yu J, Zhang D, Liu J, Li J, Yu Y, Wu XR, et al. RhoGDI SUMOylation at Lys- 138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility. J Biol Chem 2012; 287: 13752-60.
28. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 2005; 65: 9287-93.
29. Zhang D, Li J, Costa M, Gao J, Huang C. JNK1 mediates degradation HIF- 1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res 2010; 70: 813-23.
30. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007; 99: 558-68.
31. Baus D, Nonnenmacher F, Jankowski S, Doring C, Brautigam C, Frank M, et al. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 2009; 23: 1885-93.
32. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
33. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 1359-66.
34. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010; 70: 832-41.
35. Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits prostate cancer cells- And RANKL-induced osteoclastogenesis by targeting NFATc1, NF-kappaB, and AP-1 activation in RAW264.7 cells. Mol Carcinog 2014; 53: 169-80.
36. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICRmice. Mol Cancer Ther 2007; 6: 3248-55.
37. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res 2013; 19: 148-57.
38. Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014; 6: 244ra91.
39. Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 2012; 122: 2637-51.
40. Feng X, Wu Z, Wu Y, Hankey W, Prior TW, Li L, et al. Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. Mol Cell Biol 2011; 31: 3457-71.
41. Ponugoti B, Xu F, Zhang C, Tian C, Pacios S, Graves DT. FOXO1 promotes wound healing through the up-regulation of TGF-beta1 and prevention of oxidative stress. J Cell Biol 2013; 203: 327-43.
42. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006; 314: 294-7.
43. Biggs WH, 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 1999; 96: 7421-6.
44. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009; 28: 305-16.
45. Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: Interferon/ stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res 2012; 18: 3015-21.
46. Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, et al. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis 2013; 2: E59.
47. Greenwood C, Metodieva G, Al-Janabi K, Lausen B, Alldridge L, Leng L, et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics 2012; 75: 3031-40.
48. Sun Y, Cheng MK, Griffiths TR, Mellon JK, Kai B, Kriajevska M, et al. Inhibition of STAT signalling in bladder cancer by diindolylmethane: Relevance to cell adhesion,migration and proliferation. Curr Cancer Drug Targets 2013; 13: 57-68.
49. Fiorentino L, Cavalera M, Menini S, Marchetti V, Mavilio M, Fabrizi M, et al. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/ STAT1 interplay. EMBO Mol Med 2013; 5: 441-55.
50. Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 2005; 16: 183-9.